cardiovascular disease
Phase 3 results announced for Imfinzi plus Imdelltra in extensive-stage small cell lung cancer
Around 195,000 people globally will be treated for this form of lung cancer in 2026
Amgen agrees to lower prescription drug costs in deal with US government
The company has invested $40bn in US R&D and manufacturing in the past seven years
Amgen reports positive results from landmark cardiovascular study
The study found significant reductions of major cardiovascular events in high-risk adults following treatment
Amgen commits $650m to US manufacturing expansion
The investment is expected to generate up to 750 new jobs
Amgen and Kyowa Kirin announce rocatinlimab results for atopic dermatitis
The phase 3 study included around 2,600 patients
Eli Lilly’s Mounjaro shown to provide cardiovascular protection in type 2 diabetes patients
Approximately 38.4 million people in the US are affected by diabetes
Amgen’s bemarituzumab shows promise in phase 3 gastric cancer study
Almost one million new cases of gastric cancer are diagnosed globally every year
Novartis and ProFound enter cardiovascular disease collaboration worth $750m per target
The companies will aim to discover and develop new therapeutics for the group of disorders
Eli Lilly to expand cardiovascular disease pipeline with $1.3bn Verve acquisition
The deal will give Lilly access to Verve’s pipeline of gene editing medicines for atherosclerotic CVD
NewAmsterdam’s CETP inhibitor obicetrapib shows promise in Alzheimer’s sub-study
The trial was primarily designed to assess the LDL-C lowering efficacy of the candidate
Novo Nordisk’s GLP-1 drug Wegovy shows early protection against heart disease
Heart and circulatory diseases are responsible for more than 170,000 deaths in the UK every year
Amgen’s Uplizna approved by FDA as first treatment for rare disease IgG4-RD
Immunoglobulin G4-related disease affects approximately 20,000 people in the US